<DOC>
	<DOCNO>NCT00937443</DOCNO>
	<brief_summary>The incidence heart failure grow population continue age . Heart failure incidence approach 10 per 1,000 person age 65 . Although pharmacotherapy improves treatment heart failure remain insufficient prevent progression debilitate disease . Cell base therapy gain great stride last decade , launch cellular therapy mix artillery treatment chronic heart failure coronary disease . While early pre-clinical work demonstrate stem cell base therapy improve heart failure exact mechanism endothelial progenitor cell ( EPC 's ) recruit bone marrow , proliferate mediation growth factor , migrate injure tissue endogenously still remain obscured . Therefore order clinician scientist impact heart failure treatment , great understand physiological change EPC 's modulators cardioreparative process need investigation .</brief_summary>
	<brief_title>Effectiveness Walking Program Modulating Cardioreparative Factors Heart Failure</brief_title>
	<detailed_description>Heart failure remain devastate progressive chronic disease pharmacotherapy often sufficient . Although cell base therapy gain publicity treatment coronary artery disease heart failure . Determining endothelial progenitor cell recruit , proliferate , home injure tissue important area investigation . Equally important determine factor improve EPC stimulation efficiency realistic level exercise modulation various cardioreparative factor ( VEGF , NRG-1 , SDF-1 ) within heart failure patient . Since endogenous repair mechanism regulate heart failure patient effort may uncover way tip balance heart failure back normal reparative maintenance .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion criterion : 1 . Subjects 3065 year old . 2 . Subjects able give Informed Consent . 3 . Subjects give permission collection clinical demographic data electronic medical record . 4 . Subjects symptomatic ischemic nonischemic heart failure stable condition New York Heart Association class IIIII least last 3 month study enrollment . Left ventricular ejection fraction ( LVEF ) &lt; 40 % . Peak volume oxygen utilization ( peak VO2 ) &lt; 25 ml/kg/min . 5 . Patient stable dose statin initiate statin therapy . 6 . Subjects ischemic cardiomyopathy must either negative stress test within last 6 month cardiac catheterization within last year confirm stable disease . Exclusion criterion : 1 . Subjects myocardial infarction unstable angina within last six month . 2 . Subjects symptomatic severe aortic stenosis . 3 . Subjects severe HTN ( SBP &gt; 180 ) hypotension ( SBP &lt; 100 ) . 4 . Subjects pregnant . 5 . Subjects bone marrow suppression . 6 . Subjects exercise limit peripheral arterial disease . 7 . Subjects history ventricular tachycardia without implantable defibrillator 8 . Subjects decompensated diabetes ( HgA1c &gt; 10 ) . 9 . Subjects orthopedic limitation . 10 . Subjects clinical condition preclude regular participation walk exercise regimen . 11 . Subjects already participate regular physical exercise regimen great 30 minute day 5 day per week .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Physical Activity</keyword>
	<keyword>Cardiac Heart Failure</keyword>
	<keyword>Exercise Regimen</keyword>
	<keyword>Cardioreparative Factors</keyword>
</DOC>